Doxorubicin, docetaxel and cisplatin inhibited growth of mammary tumors in genetically engineered BRCA1-deficient mice. Treated tumors eventually acquired resistance to doxorubicin and docetaxel, but not to cisplatin. Here, BRCA1 is linked to breast cancer.